Waddell & Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Waddell & Associates's BMY Position: Q2 2026 in Review
Waddell & Associates reduced its Bristol-Myers Squibb (BMY) stake by 17% in Q2 2026, selling an estimated $378K and leaving 33,126 shares worth $1.91M. The position accounts for 0.09% of the portfolio, ranked #73.
Waddell & Associates first reported a position in BMY in Q2 2021 and has held it in 17 quarters since. The position peaked at $2.41M in Q1 2026. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Waddell & Associates held 33,126 shares of Bristol-Myers Squibb worth $1.91M as of Q2 2026.
- Waddell & Associates sold 6,577 Bristol-Myers Squibb shares in Q2 2026, an estimated $378K.
- Bristol-Myers Squibb made up 0.09% of Waddell & Associates's portfolio in Q2 2026, its #73 holding.
- Waddell & Associates first reported a position in Bristol-Myers Squibb in Q2 2021 and has held it in 17 quarters since.
- Waddell & Associates's Bristol-Myers Squibb position peaked at $2.41M in Q1 2026.
- 878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.